stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) EV/EBITDA
As of 5 November 2026, BioMarin Pharmaceutical Inc. (BMRN) trades at a EV/EBITDA of 38.2×. Over the past ten years it has ranged from 0.0× (June 2021) to 6,133× (March 2020); the current reading is higher than 51% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 22.6× | 3.81% |
| FY2024 | 21.7× | (66.86%) |
| FY2023 | 65.6× | (5.38%) |
| FY2022 | 69.3× | (86.82%) |
| FY2021 | 526× | 106.42% |
| FY2020 | 255× | (95.24%) |
| FY2019 | 5,358× | — |
| FY2018 | 0.0× | — |
| FY2017 | 205× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 40.2× | (16.75%) |
| Jun 2026 | 48.3× | 76.09% |
| Mar 2026 | 27.5× | 21.65% |
| Dec 2025 | 22.6× | 56.98% |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| TWST Twist Bioscience Corporation compare | n/m |
| IBRX ImmunityBio, Inc. compare | n/m |
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| SMMT Summit Therapeutics PLC compare | n/m |
| PCVX Vaxcyte, Inc. compare | n/m |
| TECH Bio-Techne Corp compare | 32.3× |
| BMRN BioMarin Pharmaceutical Inc. | 38.2× |
| CAI Caris Life Sciences,�Inc. compare | 39.4× |
| TGTX TG Therapeutics, Inc. compare | 62.0× |
| Biotechnology industry median | 0.7× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on BMRN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement